The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study

CONCLUSION: These data demonstrate the long-term effectiveness and safety of octocog alfa in patients with moderate and severe hemophilia A, especially in those receiving prophylaxis. The high number of patients receiving on-demand treatment experiencing zero bleeds could be due to selection bias within the study, with patients with less severe disease more likely to be receiving on-demand treatment.TRIAL REGISTRATION: ClinicalTrials.gov: NCT02078427.PMID:38371314 | PMC:PMC10874143 | DOI:10.1177/20406207231218624
Source: Adv Data - Category: Epidemiology Authors: Source Type: research